Volume 2, Issue 3, June 2017, Page: 51-56
Reconstructive Angioplasty During Secondary Cytoreductive Surgery Performed in Patients with Recurrent Ovarian Cancer
Boyko Valeriy, State Institution «Zaitsev V. T. Institute of General and Emergent Surgery of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
Kharchenko Kateryna, Kyiv City Clinical Oncology Centre, Kyiv, Ukraine
Prasol Vitaliy, State Institution «Zaitsev V. T. Institute of General and Emergent Surgery of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
Uderbayeva Gukmira, City Clinical Oncology Centre of Astana Akimat, Astana, Kazakhstan
Received: Jan. 27, 2017;       Accepted: Apr. 11, 2017;       Published: May 18, 2017
DOI: 10.11648/j.ijcocr.20170203.11      View  1302      Downloads  70
Abstract
Background: Tumor involvement of major vessels, especially the iliac arteries, is used to be the significant limitation for secondary cytoreductive surgery (SCRS) of recurrent ovarian cancer (ROC). Materials and Methods: Patients with ROC (n=46) who were treated in the State Establishment «Zaitsev V. T. Institute of General and Emergent Surgery of the Academy of Medical Sciences of Ukraine» during January 2009 – September 2015. All patients received SCRS with restoration and reconstructive angioplasty of the external iliac artery: I group (n=24) – alloprosthesis; II group (n=22) – autoartery angioplasty. Results: Duration of surgery was in Group I and Group II 466.3±11.2 min vs 454.8±10.3 min respectively, р>0.05. Postoperative complications occurred in 10 (21.7%) patients (25% in Group I; 18.2% in Group II). The incidence of nonspecific early postoperative complications was 25% in Group I and 19.1% in Group II; p=0.3. The incidence of specific complications was higher in allograft group (12.3% vs 4.5%; р=0.036). There was statistically significant difference between the groups in stage distribution of postoperative complications (р=0.03). There were no cases of late specific and non-specific complications. Postoperative mortality was 0%. Duration of hospital stay in Group I was 21.5±2.3 days vs 12.1±1.7 days; in Group II, p=0.02. SCRS was optimal in all cases. Median follow-up was 42.5 months (range 7-64 months). There was no significant difference among groups in the recurrence rate, medians disease-free and overall survival. Conclusion: Usage of the internal iliac artery as autograft during SCRS with restoration and reconstruction angioplasty of external iliac artery leads to reducing risk of specific complications (infection, rejection) and prevents development of destructive processes in the graft wall. There is no negative impact of such surgical approach on the rates of recurrence and overall survival of ROC patients.
Keywords
Ovarian Cancer, Recurrence, Treatment, Secondary Cytoreductive Surgery, Angioplasty
To cite this article
Boyko Valeriy, Kharchenko Kateryna, Prasol Vitaliy, Uderbayeva Gukmira, Reconstructive Angioplasty During Secondary Cytoreductive Surgery Performed in Patients with Recurrent Ovarian Cancer, International Journal of Clinical Oncology and Cancer Research. Vol. 2, No. 3, 2017, pp. 51-56. doi: 10.11648/j.ijcocr.20170203.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Aghajanian С., Blank S. V., Goff B. A. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; 14(17): 2039–45.
[2]
Bae J., Lim M. C., Choi J. H. et al. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol. 2009; 20(2): 101-6.
[3]
Belov Y. V. Manual of Vascular Surgery with atlas of operative technique. Moscow:Ltd. "Medical News Agency". 2011. 464 p.
[4]
Bokeria L. A. Aortic aneurysms. Moscow: Medicine. 2001. 204 p.
[5]
Boyko V. V., Prasol V. A., Bogdan V. N. et al. The use of advanced ultrasound diagnostics of neointimal hyperplasia in the femoral artery synthetic prosthesis anastomosis. Kharkiv surgical school. 2005; 3: 24-5.
[6]
Bristow R. E., Puri I., Chi D. S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009; 14(1): 265–74.
[7]
Carpenter S. G, Stone W. M., Bower T. C. et al: Surgical management of tumors invading the aorta and major arterial structures. Ann vasc surg. 2011; 25: 1026-35.
[8]
Chen L. M., Karlan B. Y. Recurrent ovarian carcinoma: is there a place for surgery? Semin Surg Oncol. 2000; 19: 62-8.
[9]
Clavien P. A., Barkun О., De Oliveira M. L. et al: The Сlavien-Dindo classification of surgical complications: five-year experience. Ann surg. 2009; 250: 187-96.
[10]
Clinical Angiology: Manual (Ed. Pokrovsky A. V.). Vol 1. Moscow: JSC "Publishing house Medicine". 2004. 808 p.
[11]
Eisenkop S. M., Friedman R. L., Spirtos N. M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000; 88: 144-53.
[12]
Ghosh J., Bhowmick A., Baguneid M. Oncovascular surgery. EJSO. 2011; 37: 1017–24.
[13]
Gornall R. J., Standfield N., DeSouza N. M. et al. Resection of recurrent bulky gynaecological side wall malignancy with iliac vessel reconstruction. Br J Obst Gyn. 2001; 108: 1305–8.
[14]
Gusinsky A. V. Comparative assessment of the effectiveness of different types of vascular prostheses and the surgical treatment of angioplasty in atherosclerotic lesions of the aorta and the arteries of the lower extremities. Abstract of Doctor of Medical Sciences, St. Petersburg, 2003.
[15]
Kormosh N. G., Laktionov K. P. Surgical strategy in relapsed ovarian cancer. Oncogynecology. 2014; 2: 17-26.
[16]
Lentz S. E., Tierney K. E., Weaver F. A. et al. Abdominal aortic resection and Y-graft placement to achieve complete cytoreduction in stage IIIc ovarian carcinoma. Obstetrics & Gynecology. 2014; 123(2): 486–8.
[17]
Lorusso D., Mancini M., Di Rocco R et al. The Role of Secondary Surgery in Recurrent Ovarian Cancer. Int J Surg Onc. 2012; 2012: 1-6.
[18]
Luvero D., Milani A., Ledermann J. A. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014; 6(5): 229–39.
[19]
Lyzikov A. A. The use of artificial vascular prostheses in vascular reconstructions. Surgery News. 2010; 18(4): 135-45.
[20]
McGoldrick N. P, Butler J. S., Lavelle M. et al. Resection and reconstruction of pelvic and extremity soft tissue sarcomas with major vascular involvement: current concepts. World J Orthop. 2016; 7(5): 293-300.
[21]
Moroz A. N. Prognostic factors of false aneurysms anastomosis occurrence. Kharkiv surgical school. 2006; 2: 103-4.
[22]
Novikova E. G., Moskovskaya E. J. Causes, diagnosis and treatment of ovarian cancer recurrences. The literature review and analysis of the own data. Oncology. Herzen Journal. 2015; 3: 59-67.
[23]
Parmar M. K., Ledermann J. A., Colombo N. et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 14(9375): 2099–106.
[24]
Pfisterer J., Vergote I., Du Bois A. et al. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int j Gynecol Cancer. 2005; 14(s1): 36–41.
[25]
Salani R., Santillan A., Zahurak M. L. et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. Analysis of prognostic factors and survival outcome. Cancer. 2007; 109: 685–91.
[26]
Sarkissian A. S. Surgical treatment of thrombosis and false aneurysms of alloprostethis after primary reconstructive operations. Medical science NAS of Armenia. 2013; 2: 87-94.
[27]
Song T. K, Harris E. J, Raghavan S. et al: Major blood vessel reconstruction during sarcoma surgery. Arch surg. 2009; 144: 817-22.
[28]
Standards for the diagnosis and treatment of cancer patients. Orders of the Ministry of Health of Ukraine №544 (17.09.2007), №645 (07.30.10), №247 (29.04.2011). (http://www.unci.org.ua/standarts1.html)
[29]
Vascular surgery by Khaimovich (Ed. by Asher E.). Moscow: Binom. Knowledge Laboratory. 2012; 1: 500-6.
[30]
Vasilev V. O., Belyi V. Y., Shudrak A. A. et al. Oncovascular surgery of the abdominal cavity and retroperitoneal space. Science and practice. 2014; 1(2): 112-5.
[31]
Whitney C. W, Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. Philadelphia: Gynecologic Oncology Group; 2009. https://gogmember.gog.org/manuals/pdf/surgman.pdf
[32]
Zang R. Y., Harter P., Chi D. S. et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011; 105(7): 890–6.
Browse journals by subject